Designing Longevity
Skip to main content

Compare Peptide Options for Keeping Weight Off

If treatment has helped, start by planning how you can keep it going or what happens if you need to change it. In two randomized trials, people who continued their existing treatment kept more weight off than those who switched to placebo.

Read more

The trials started with different medicines and different groups. They did not compare the medicines directly or test every lower dose, taper, switch, or tablet.

Sources reviewed

Compare by the treatment you started with

  • Continuing Zepbound injections

    FDA-approved for long-term weight reduction in eligible adults

    In SURMOUNT-4, adults without diabetes who had completed the initial tirzepatide phase were randomized to continue or switch to placebo. From that point, average weight fell another 5.5% with continued treatment and rose 14.0% with placebo over 52 weeks.

    The continuation groups studied 10 mg or 15 mg as their maximum tolerated dose. These results do not settle what happens at a different dose or after a switch.

  • Continuing Wegovy injections

    FDA-approved for long-term weight reduction in eligible patients

    In STEP 4, adults without diabetes who reached weekly semaglutide 2.4 mg were randomized to continue or switch to placebo. From that point, average weight fell another 7.9% with continued treatment and rose 6.9% with placebo over 48 weeks.

    This trial studied injections. It does not establish the same result for Wegovy tablets or the 7.2 mg injection.

  • Saxenda after initial weight loss

    FDA-approved for long-term weight reduction in eligible patients

    SCALE Maintenance studied liraglutide in adults who had already lost weight in a low-calorie-diet program. The study found that more participants on liraglutide maintained their earlier loss over 56 weeks than participants on placebo.

    This was a different starting point from continuing a medicine that had already worked. It does not answer whether to switch from another treatment.

  • Continuing Imcivree for a specific diagnosis

    FDA-approved for specific causes of obesity

    If your diagnosis is covered in the Imcivree label, the care team can explain what response it tracks and how the specialty pharmacy manages refills.

    This applies to the labeled rare genetic or acquired hypothalamic causes. The general-obesity trials above do not answer this question.

Plan your next step

See a problem or outdated information? Tell us.